Literature DB >> 26507850

Minimal invasive lung support via umbilical vein with a double-lumen cannula in a neonatal lamb model: a proof of principle.

Florian Schmidt1, J Kuebler2, M Ganter3, T Jack4, L Meschenmoser5, M Sasse4, M Boehne4, H Bertram4, P Beerbaum4, H Koeditz4.   

Abstract

PURPOSE: Acute respiratory distress syndrome, with the need for invasive mechanical ventilation (MV) remains a major cause of neonatal mortality and morbidity. Although venovenous extracorporeal lung support (VV-ECLS) has become a standard of care procedure in neonatal patients with acute pulmonary failure there are no reports regarding the use of a double-lumen cannula for extracorporeal minimal invasive lung support via the umbilical vein.
METHODS: A neonatal lamb model was used (n = 3). Umbilical vein was cannulated with a double-lumen catheter allowing venovenous extracorporeal gas exchange. Cannula was positioned with its tip in the right atrium. VV-ECLS was started and ventilation was stopped. Providing oxygenation and CO2 removal solely through VV-ECLS hemodynamics, blood gases were measured.
RESULTS: Total VV-ECLS without MV was applied to all three neonatal lambs. Time on venovenous ECLS was 60, 120 and 120 min. Initial pCO2 was 60, 56 and 65 mmHg compared to 31, 32 and 32 mmHg at the end of VV-ECLS. Initial pO2 was 30, 27 and 26 mmHg compared to 22, 19 and 23 mmHg. Initial lactate was 5, 10 and 3.7 mmol/l compared to 13.3, 12.6 and 11.3 mmol/l at the end of VV-ECLS. MAP at baseline was 51, 52 and 65 mmHg compared to 36, 38 and 41 mmHg at the end of VV-ECLS. In all three lambs inotropes were admitted to maintain MAD >35 mmHg.
CONCLUSION: Even without mechanical ventilation we were able to sufficiently remove pCO2 with our new minimal invasive VV-ECLS using a double-lumen catheter via the umbilical vein, supporting the idea of a lung protective strategy in neonatal acute respiratory failure. pO2 was measured 22, 19 and 23 mmHg, respectively, at the end of VV-ECLS, at least partially caused by recirculation phenomenon, which could possibly be improved by different cannula design. Inotropic support was necessary during VV-ECLS to achieve targeted MAD > 35 mmHg. While technically feasible, this new approach might allow further research in the field of extracorporeal lung support and therefore will follow the concept of a lung protective strategy in acute neonatal respiratory failure.

Entities:  

Keywords:  Double-lumen cannula; Neonatal acute respiratory failure; Neonatal lamb model; Neonatal minimal invasive lung support; Umbilical vein; Venovenous extracorporeal lung support

Mesh:

Year:  2015        PMID: 26507850     DOI: 10.1007/s00383-015-3815-8

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  24 in total

1.  Leukopenia associated with extracorporeal membrane oxygenation in newborn infants.

Authors:  T L Zach; R H Steinhorn; M K Georgieff; M M Mills; T P Green
Journal:  J Pediatr       Date:  1990-03       Impact factor: 4.406

Review 2.  A review of venovenous and venoarterial extracorporeal membrane oxygenation in neonates and children.

Authors:  S J Keckler; C A Laituri; D J Ostlie; S D St Peter
Journal:  Eur J Pediatr Surg       Date:  2009-09-10       Impact factor: 2.191

3.  Experience with the Avalon® bicaval double-lumen veno-venous cannula for neonatal respiratory ECMO.

Authors:  S Speggiorin; S G Robinson; C Harvey; C Westrope; G M Faulkner; P Kirkland; G J Peek
Journal:  Perfusion       Date:  2014-06-27       Impact factor: 1.972

4.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

Authors:  Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

5.  Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants.

Authors:  Matthew M Laughon; John C Langer; Carl L Bose; P Brian Smith; Namasivayam Ambalavanan; Kathleen A Kennedy; Barbara J Stoll; Susie Buchter; Abbot R Laptook; Richard A Ehrenkranz; C Michael Cotten; Deanne E Wilson-Costello; Seetha Shankaran; Krisa P Van Meurs; Alexis S Davis; Marie G Gantz; Neil N Finer; Bradley A Yoder; Roger G Faix; Waldemar A Carlo; Kurt R Schibler; Nancy S Newman; Wade Rich; Abhik Das; Rosemary D Higgins; Michele C Walsh
Journal:  Am J Respir Crit Care Med       Date:  2011-03-04       Impact factor: 21.405

6.  Primary use of the venovenous approach for extracorporeal membrane oxygenation in pediatric acute respiratory failure.

Authors:  Robert Pettignano; James D Fortenberry; Micheal L Heard; Michele D Labuz; Kenneth C Kesser; April J Tanner; Scott F Wagoner; Judith Heggen
Journal:  Pediatr Crit Care Med       Date:  2003-07       Impact factor: 3.624

7.  Venovenous extracorporeal membrane oxygenation in newborn infants using the umbilical vein as a reinfusion route.

Authors:  J Kato; M Nagaya; N Niimi; S Tanaka
Journal:  J Pediatr Surg       Date:  1998-09       Impact factor: 2.545

Review 8.  Bicaval dual-lumen cannula for venovenous extracorporeal membrane oxygenation: Avalon© cannula in childhood disease.

Authors:  D Berdajs
Journal:  Perfusion       Date:  2014-07-28       Impact factor: 1.972

9.  Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study.

Authors:  Thomas Bein; Steffen Weber-Carstens; Anton Goldmann; Thomas Müller; Thomas Staudinger; Jörg Brederlau; Ralf Muellenbach; Rolf Dembinski; Bernhard M Graf; Marlene Wewalka; Alois Philipp; Klaus-Dieter Wernecke; Matthias Lubnow; Arthur S Slutsky
Journal:  Intensive Care Med       Date:  2013-01-10       Impact factor: 17.440

10.  Complement activation by in vivo neonatal and in vitro extracorporeal membrane oxygenation.

Authors:  Johannes Graulich; Joseph Sonntag; Monika Marcinkowski; Karl Bauer; Hans Kössel; Christoph Bührer; Michael Obladen; Hans T Versmold
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.